| Literature DB >> 31803022 |
Walter J Jermakowicz1, Melissa M Carballosa-Gautam1, Alberto A Vitores1, Ian D Hentall1.
Abstract
The spinal cord after injury shows altered transcription in numerous genes. We tested in a pilot study whether the nucleus raphé magnus, a descending serotonergic brainstem region whose stimulation improves recovery after incomplete spinal cord injury (SCI), can influence these transcriptional changes. Rats received 2 h of low-frequency electrical stimulation in the raphé magnus 3 days after an impact contusion at segment T8. Comparison groups lacked injuries or activated stimulators or both. Immediately following stimulation, spinal cords were extracted, their RNA transcriptome sequenced, and differential gene expression quantified. Confirming many previous studies, injury primarily increased inflammatory and immune transcripts and decreased those related to lipid and cholesterol synthesis and neuronal signaling. Stimulation plus injury, contrasted with injury alone, caused significant changes in 43 transcripts (39 increases, 4 decreases), all protein-coding. Injury itself decreased only four of these 43 transcripts, all reversed by stimulation, and increased none of them. The non-specific 5-HT7 receptor antagonist pimozide reversed 25 of the 43 changes. Stimulation in intact rats principally caused decreases in transcripts related to oxidative phosphorylation, none of which were altered by stimulation in injury. Gene ontology (biological process) annotations comparing stimulation with either no stimulation or pimozide treatment in injured rats highlighted defense responses to lipopolysaccharides and microorganisms, and also erythrocyte development and oxygen transport (possibly yielding cellular oxidant detoxification). Connectivity maps of human orthologous genes generated in the CLUE database of perturbagen-response transcriptional signatures showed that drug classes whose effects in injured rats most closely resembled stimulation without pimozide include peroxisome proliferator-activated receptor agonists and angiotensin receptor blockers, which are reportedly beneficial in SCI. Thus the initial transcriptional response of the injured spinal cord to raphé magnus stimulation is upregulation of genes that in various ways are mostly protective, some probably located in recently arrived myeloid cells.Entities:
Keywords: electrical stimulation; mRNA; raphe magnus nucleus; rat (Brown Norway); spinal cord injury
Year: 2019 PMID: 31803022 PMCID: PMC6877476 DOI: 10.3389/fncel.2019.00510
Source DB: PubMed Journal: Front Cell Neurosci ISSN: 1662-5102 Impact factor: 5.505
Groups and contrasts analyzed.
| ±SCI(0), B/A | B, | No | No | 982(922/60) | 1047 | |
| A, | No | No | ||||
| ±st(SCI), C/B | C, | Yes | No | 43(39/4) | 327 | |
| B, | Yes | No | ||||
| ±pim(st/SCI), D/C | D, | Yes | Yes | 81(52/29) | 601 | |
| C, | Yes | Yes | ||||
| ±st(0), E/A | E, | No | No | 28(20/8) | 226 | |
| A, | No | No | ||||
| ±st/SCI(0), C/A | C, | No | 1150(1084/66) | 854 | ||
| A, | No | |||||
| ±SCI(st), C/E | C, | Yes | No | 1374(1205/168) | 911 | |
| E, | Yes | No |
Genes altered by stimulation in injured animals, selected by contrast ±st(SCI).
| ∗Similar to 60S ribosomal protein L12 ( | –6.63 | 7.12 | –10.44 | ||
| ∗Cathepsin G ( | 3.90 | –2.26 | 2.55 | ||
| ∗Carbonic anhydrase I ( | 3.78 | –2.49 | |||
| ∗Defensin NP-4 precursor ( | 3.69 | –2.85 | 2.35 | ||
| ∗Matrix metallopeptidase 13 ( | –1.85 | 3.55 | –3.17 | 1.70 | 2.41 |
| ∗Defensin alpha 5 ( | 3.31 | –3.36 | 1.83 | 2.45 | |
| Rh-associated glycoprotein ( | 3.18 | 2.86 | |||
| Pro-platelet basic protein ( | 2.92 | –4.08 | 2.14 | 4.13 | |
| ∗Myeloperoxidase ( | 2.86 | –2.42 | 1.71 | 2.72 | |
| ∗Hemogen ( | 2.63 | –2.65 | 2.23 | ||
| ∗Neutrophilic granule protein ( | 2.60 | –1.62 | 1.57 | ||
| Rh blood group, D antigen ( | 2.54 | –2.49 | 1.84 | 1.95 | |
| ∗Defensin RatNP-3 precursor ( | 2.50 | –2.99 | 2.70 | ||
| ∗S100 calcium binding protein A8 ( | 2.37 | –2.22 | 2.10 | 1.74 | |
| ∗Solute carrier family 4, member 1 ( | 2.36 | –1.93 | 2.26 | ||
| Elastase, neutrophil expressed ( | 2.35 | –3.00 | 2.93 | ||
| ∗S100 calcium binding protein A9 ( | 2.35 | –1.86 | 1.83 | 1.57 | |
| Eosinophil peroxidase ( | 2.30 | ||||
| ∗Alpha hemoglobin stabilizing protein ( | 2.29 | –2.48 | 2.05 | ||
| Multimerin 1 ( | 2.24 | 1.90 | |||
| ∗Cathelicidin antimicrobial peptide ( | 2.16 | 1.36 | 1.75 | ||
| Erythroblast membrane-associated protein ( | 2.10 | 2.08 | |||
| ATP binding cassette subfam. A member 13 ( | 2.04 | 1.66 | |||
| Kell blood group, metallo-endopeptidase ( | 2.00 | 2.47 | |||
| Kruppel like factor 1 ( | 2.00 | 1.52 | 1.75 | ||
| Interleukin-23 receptor-like ( | 1.92 | –2.74 | |||
| Nuclear factor, erythroid 2 ( | 1.87 | 1.99 | |||
| Roundabout homolog 1 | 1.82 | 2.13 | 2.09 | ||
| 5′-aminolevulinate synthase 2 ( | 1.75 | –1.99 | 1.53 | ||
| T-cell Ig and mucin domain containing 2 ( | 1.71 | 3.25 | 3.08 | ||
| Hemoglobin, alpha 2 ( | 1.68 | –2.03 | 1.28 | ||
| Ficolin B ( | 1.65 | 2.71 | 2.70 | ||
| Hemoglobin, alpha 1 ( | –1.11 | 1.61 | –1.89 | 1.17 | |
| Beta globin minor gene ( | 1.58 | –1.66 | 1.06 | ||
| Aquaporin 1 ( | 1.54 | 1.57 | |||
| Hemoglobin subunit beta ( | –1.14 | 1.49 | –1.66 | ||
| Erythrocyte membrane protein band 4.2 ( | 1.45 | 1.31 | |||
| Hemoglobin, beta adult major chain ( | 1.30 | –1.89 | 1.20 | ||
| Integrin subunit alpha 2b ( | 1.12 | 1.23 | |||
| AABR07043748.1 (unmapped) | –1.47 | ||||
| Solute carrier family 17 member 7 ( | –2.16 | –2.57 | –2.97 | ||
| Guanylate binding protein family member 6 ( | –4.50 | 5.56 | –3.73 | –4.31 | |
| AABR07043200.1 (uncharacterized) | –6.33 | –6.47 | –6.22 |
Genes selected by contrast ±st(0) (effect of stimulation in non-injured rats).
| AABR07007730.1 (unmapped) | Processed_pseudogene | 6.01 | 6.87 | |
| Kallikrein B1 ( | Protein_coding | 5.73 | 6.22 | |
| Rn50_X_0694.1 (unmapped) | Processed_pseudogene | 5.70 | ||
| Similar to Tpi1 protein ( | Processed_pseudogene | 3.77 | ||
| AABR07021745.1 (unmapped) | Small nuclear RNA | 2.05 | 3.87 | |
| Prothymosin alpha ( | Protein_coding | 1.99 | ||
| AC127784.3 (unmapped) | Small nucleolar RNA | 1.79 | 1.94 | |
| Neutrophil immunoglobulin-like receptor 1 ( | Protein_coding | 1.77 | 3.45 | |
| AC129753.3 (unmapped) | Small nucleolar RNA | 1.73 | 2.84 | |
| Leukocyte immunoglobulin-like receptor ( | Protein coding | 1.71 | 2.99 | |
| AABR07067449.1 (unmapped) | Small nucleolar RNA | 1.51 | ||
| AC118113.1 (unmapped) | Small nucleolar RNA | 1.46 | ||
| AC112093.1 (unmapped) | Small nucleolar RNA | 1.25 | ||
| AC097575.3 (unmapped) | Small nuclear RNA | 1.24 | 1.58 | |
| AABR07005613.1 (unmapped) | Miscellaneous_RNA | 1.22 | ||
| AABR07050379.1 (unmapped) | Small nuclear RNA | 1.22 | 2.02 | |
| AABR07072283.4 (unmapped) | Small Cajal body-specific RNA | 1.18 | ||
| Flavin containing monooxygenase 3 ( | Protein coding | 1.15 | ||
| Ribosomal_L22 domain containing protein ( | Protein coding | 1.10 | ||
| AABR07036645.1 (unmapped) | Small nucleolar RNA | 1.08 | 1.39 | |
| AC094643.2 (unmapped) | Protein coding | –1.02 | ||
| ATPase subunit 8 ( | Protein coding | –1.04 | ||
| Early growth response 1 ( | Protein coding | –1.07 | ||
| Cytochrome b ( | Protein coding | –1.12 | ||
| NADH dehydrogenase subunit 2 ( | Protein coding | –1.20 | ||
| NADH dehydrogenase subunit 4L ( | Protein coding | –1.52 | ||
| TNF receptor superfamily member 14 ( | Protein coding | –2.03 | ||
| Major intrinsic protein of lens fiber ( | Protein coding | –3.01 |
FIGURE 1Normalized RNA molecular counts from individual rats for 14 characterized genes identified as prominently up-regulated (n = 12) or down-regulated (n = 2) by stimulation. The included genes were those flagged by all three contrasts ±st(SCI), ±SCI(st) and ±st/SCI(0), as listed in Table 2. The vertical axis is scaled logarithmically and log zero values (equal to –∞) are presented separately off-scale.
Top canonical pathways indicated by IPA for the effects of injury alone [±SCI(0)], of stimulation after injury [±st(SCI)], stimulation on intact rats [±st(0)], and of pimozide on injured, stimulated rats [±pim(st/SCI)].
| EIF2 signaling | 4.59E−27 | 35.3% 78/221 |
| TREM1 signaling | 1.98E−16 | 45.3% 34/75 |
| Role of macrophages, fibroblasts, and endothelial cells in rheumatoid arthritis | 1.90E−14 | 23.6% 73/309 |
| Fc receptor-mediated phagocytosis in macrophages and monocytes | 7.15E−14 | 37.6% 35/93 |
| Role of pattern recognition receptors in recognition of bacteria and viruses | 1.75E−13 | 31.4% 43/137 |
| Superpathway of cholesterol biosynthesis | 9.06E−18 | 60.7% 17/28 |
| Cholesterol biosynthesis I | 1.56E−12 | 76.9% 10/13 |
| Cholesterol biosynthesis II (via 24,25-dihydrolanosterol) 1.56E−12 | 1.56E−12 | 76.9% 10/13 |
| Cholesterol biosynthesis III (via desmosterol) | 1.56E−12 | 76.9% 10/13 |
| Synaptic long term depression | 1.43E−09 | 16.4% 24/146 |
| Role of IL-17A in psoriasis | 2.13E−04 | 15.4% 2/13 |
| Osteoarthritis pathway | 5.34E−03 | 1.4% 3/211 |
| Tetrapyrrole biosynthesis II | 8.40E−03 | 20.0% 1/5 |
| Heme biosynthesis II | 1.51E−02 | 11.1% 1/9 |
| Atherosclerosis signaling | 1.94E−02 | 1.6% 2/127 |
| Oxidative phosphorylation | 1.21E−11 | 7.3% 8/109 |
| Mitochondrial dysfunction | 4.54E−10 | 4.7% 8/171 |
| Sirtuin signaling pathway | 9.91E−06 | 2.1% 6/291 |
| Glycine degradation (creatine biosynthesis) | 3.46E−03 | 50.0% 1/2 |
| MSP-RON signaling pathway | 6.92E−03 | 2.8% 2/72 |
| Role of IL-17A in psoriasis | 2.38E−04 | 15.4% 2/13 |
| G protein signaling mediated by tubby | 1.48E−03 | 6.2% 2/32 |
| Tec kinase signaling | 3.41E−03 | 1.8% 3/170 |
| RhoGDI signaling | 3.82E−03 | 1.7% 3/177 |
| Agranulocyte adhesion and diapedesis | 4.72E−03 | 1.6% 3/191 |
Gene Ontology terms (biological process, GOTERM_BP_DIRECT) found to be enriched in by stimulation after injury [±st(SCI)] or its modification by pimozide [±pim(st/SCI)].
| Defense response to fungus | 0050832 | 6.52E−08 | 6.74E−08 | |
| Erythrocyte development | 0048821 | 1.60E−07 | 5.81E−04 | |
| Oxygen transport | 0015671 | 4.25E−06 | 6.20E−06 | |
| Leukocyte migration involved in inflammatory response | 0002523 | 2.02E−04 | 1.86E−04 | |
| Defense response to bacterium | 0042742 | 3.44E−04 | 3.83E−03 | 1.62E−02 |
| Negative regulation of growth of symbiont in host | 0044130 | 3.59E−04 | 1.33E−02 | |
| Hydrogen peroxide catabolic process | 0042744 | 3.61E−04 | 3.31E−04 | |
| Killing of cells of other organism | 0031640 | 4.36E−04 | 5.04E−04 | |
| Ammonium transport | 0015696 | 2.69E−03 | ||
| Ammonium transmembrane transport | 0072488 | 4.14E−03 | ||
| Response to lipopolysaccharide | 0032496 | 6.48E−03 | 7.80E−04 | 1.98E−09 |
| Chronic inflammatory response | 0002544 | 7.43E−03 | ||
| Cellular oxidant detoxification | 0098869 | 8.26E−03 | 8.18E−03 | |
| Response to yeast | 0001878 | 8.55E−03 | ||
| Response to hydrogen peroxide | 0042542 | 1.02E−02 | 1.08E−02 | |
| Defense response to Gram-positive bacterium | 0050830 | 1.55E−02 | 2.67E−07 | |
| Innate immune response | 0045087 | 3.20E−02 | 9.36E−05 | 1.86E−13 |
| Antibacterial humoral response | 0019731 | 3.23E−02 | ||
| Response to virus | 0009615 | 7.13E−04 | 4.20E−04 | |
| Defense response to virus | 0051607 | 3.64E−03 | 1.07E−08 |
Perturbagens (pharmacologic and genetic) whose expression signatures most closely resemble the effect of stimulation after injury and its modification by pimozide.
| PPAR receptor agonist | 99.78 | 99.97 |
| Nucleoporin LOF | 99.59 | 99.73 |
| Phospholipases GOF | 99.46 | 81.78 |
| Structural maintenance of chromosomes proteins LOF | 99.40 | <80% |
| Angiotensin receptor antagonist | 99.02 | 99.22 |
| Wnt family GOF | 98.55 | 96.27 |
| SRC inhibitor | 98.53 | <80% |
| Potassium channel blocker | 98.37 | <80% |
| Glucocorticoid receptor agonist | 98.24 | 98.48 |
| Imidazoline ligand | 97.9 | <80% |
| Bacterial DNA gyrase inhibitor | 97.87 | <80% |
| SRY LOF | 97.61 | 93.55 |
| NFkB pathway inhibitor | 97.14 | 87.87 |
| HMGCR inhibitor | 96.44 | <80% |
| FOS transcription factor family GOF | 96.18 | 99.8 |
| Heat shock 70 kDa proteins LOF | 95.71 | <80% |
| Proteasome pathway LOF | 95.30 | <80% |
| NKL subclass homeoboxes and pseudogenes LOF | 94.86 | <80% |
| Serine proteases GOF | 94.59 | 98.28 |
| Na-K-Cl transporter inhibitor | 94.5 | 88.32 |